bpc 157 pda Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing PDA (BPC-157-Arginine) | American Wellness

Four weeks at 0.25mg uses 1mg

International scheduling Australia's Therapeutic Goods Administration (interim decision, April 2024) and New Zealand's Medsafe (Medicines Classification Committee, June 2025) have moved to schedule BPC-157 as a prescription-only medicine, despite its unavailability through legitimate prescription

In animal models, it has reduced infarct size, improved heart function after ischemia, and even reversed agerelated stiffening of the heart muscle

The origins of todays BPC-157 buzz lie in a laboratory in post-communist Croatia, and with its leader, Predrag Sikiric, a professor of pharmacology at the University of Zagreb